X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4279) 4279
Book Chapter (52) 52
Newsletter (46) 46
Newspaper Article (32) 32
Magazine Article (29) 29
Book / eBook (15) 15
Reference (6) 6
Dissertation (3) 3
Government Document (3) 3
Web Resource (3) 3
Conference Proceeding (2) 2
Book Review (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3853) 3853
science & technology (2920) 2920
life sciences & biomedicine (2875) 2875
thalidomide - adverse effects (2388) 2388
female (2099) 2099
male (1945) 1945
thalidomide - therapeutic use (1770) 1770
thalidomide (1587) 1587
middle aged (1546) 1546
thalidomide - analogs & derivatives (1459) 1459
aged (1376) 1376
thalidomide - administration & dosage (1306) 1306
multiple myeloma - drug therapy (1286) 1286
adult (1158) 1158
hematology (1095) 1095
oncology (1095) 1095
multiple myeloma (1000) 1000
treatment outcome (968) 968
antineoplastic combined chemotherapy protocols - therapeutic use (770) 770
lenalidomide (644) 644
aged, 80 and over (548) 548
antineoplastic combined chemotherapy protocols - adverse effects (517) 517
care and treatment (506) 506
bortezomib (502) 502
antineoplastic agents - therapeutic use (497) 497
dexamethasone - administration & dosage (476) 476
abridged index medicus (468) 468
animals (407) 407
drug therapy (388) 388
antineoplastic agents - adverse effects (374) 374
pregnancy (373) 373
pharmacology & pharmacy (349) 349
angiogenesis inhibitors - therapeutic use (342) 342
medicine & public health (336) 336
recurrence (335) 335
thalidomide - pharmacology (313) 313
cancer (312) 312
immunosuppressive agents - therapeutic use (311) 311
dexamethasone (309) 309
disease-free survival (309) 309
multiple myeloma - mortality (297) 297
aids/hiv (296) 296
research (290) 290
angiogenesis inhibitors - adverse effects (274) 274
dermatology (268) 268
immunosuppressive agents - adverse effects (260) 260
multiple myeloma - pathology (260) 260
chemotherapy (251) 251
dose-response relationship, drug (248) 248
general & internal medicine (236) 236
follow-up studies (235) 235
retrospective studies (234) 234
medicine, general & internal (231) 231
antineoplastic combined chemotherapy protocols - administration & dosage (230) 230
clinical trials (230) 230
risk factors (230) 230
abnormalities, drug-induced (229) 229
clinical trials as topic (228) 228
hematology, oncology and palliative medicine (226) 226
multiple myeloma - therapy (217) 217
prognosis (215) 215
health aspects (213) 213
immunologic factors - therapeutic use (210) 210
survival analysis (209) 209
drug therapy, combination (208) 208
analysis (206) 206
child (206) 206
dosage and administration (204) 204
drug administration schedule (203) 203
dexamethasone - adverse effects (199) 199
remission induction (198) 198
multiple myeloma - complications (196) 196
disease progression (192) 192
adolescent (191) 191
patients (190) 190
transplantation (189) 189
survival rate (184) 184
angiogenesis inhibitors (171) 171
antineoplastic agents - administration & dosage (170) 170
dexamethasone - therapeutic use (170) 170
boronic acids - administration & dosage (169) 169
pyrazines - administration & dosage (169) 169
time factors (165) 165
stem cells (161) 161
multiple myeloma - diagnosis (159) 159
medical research (155) 155
myelodysplastic syndromes - drug therapy (155) 155
boronic acids - therapeutic use (154) 154
pyrazines - therapeutic use (154) 154
angiogenesis inhibitors - administration & dosage (149) 149
peripheral nervous system diseases - chemically induced (149) 149
immunologic factors - adverse effects (148) 148
administration, oral (147) 147
complications and side effects (147) 147
combined modality therapy (145) 145
myeloma (142) 142
infant, newborn (141) 141
transplantation, autologous (141) 141
immunosuppressive agents - administration & dosage (139) 139
immunology (132) 132
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (6) 6
Robarts - Stacks (4) 4
UTL at Downsview - May be requested (4) 4
Online Resources - Online (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Criminology - Stacks (1) 1
East Asian (Cheng Yu Tung) - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
Music - Stacks (1) 1
OISE - May be requested in 6-10 wks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4070) 4070
German (171) 171
Japanese (69) 69
French (62) 62
Spanish (37) 37
Chinese (27) 27
Portuguese (16) 16
Swedish (15) 15
Italian (13) 13
Dutch (11) 11
Czech (9) 9
Polish (9) 9
Russian (8) 8
Hebrew (6) 6
Danish (5) 5
Finnish (4) 4
Hungarian (4) 4
Norwegian (4) 4
Ukrainian (3) 3
Korean (2) 2
Serbian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical journal of the American Society of Nephrology, ISSN 1555-9041, 01/2017, Volume 12, Issue 1, pp. 176 - 189
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 21, pp. 1572 - 1587
..., interleukin-2, ipilimumab, tremelimumab, thalidomide, and lenalidomide. Primary hypothyroidism is the most common side effect, although thyrotoxicosis and effects on thyroid... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Hypothyroidism - chemically induced | Thyroid Function Tests | Hyperthyroidism - diagnosis | Interleukin-2 - adverse effects | Recombinant Fusion Proteins - adverse effects | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Antineoplastic Agents - administration & dosage | Recombinant Proteins - adverse effects | Tetrahydronaphthalenes - adverse effects | Hyperthyroidism - chemically induced | Thalidomide - analogs & derivatives | Antineoplastic Agents - adverse effects | Diphtheria Toxin - adverse effects | Thyroid Hormones - blood | Anticarcinogenic Agents - adverse effects | Interleukin-2 - analogs & derivatives | Thyroiditis, Autoimmune - chemically induced | Molecular Targeted Therapy - methods | Thyroid Gland - drug effects | Thalidomide - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Hyperthyroidism - blood | Radioimmunotherapy | Hypopituitarism - etiology | Hypothyroidism - diagnosis | Alemtuzumab | Hypothyroidism - etiology | Neoplasms - drug therapy | Iodine Radioisotopes - administration & dosage | Hypopituitarism - complications | Neoplasms - immunology | Hypothyroidism - drug therapy | Quality of Life | Interferon-alpha - adverse effects | Hypothyroidism - blood | Thyroid Gland - metabolism | Antibodies, Neoplasm - adverse effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Complications and side effects | Usage | Thyroid diseases | Diagnosis | Antineoplastic agents | Thyroid gland function tests | Risk factors | Index Medicus | Review
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2014, Volume 371, Issue 10, pp. 895 - 905
.... However, since autologous stem-cell transplantation has substantial toxic effects and requires prolonged hospitalization, the comparison with less toxic, orally administered treatments is important... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Leukemia, ISSN 0887-6924, 12/2008, Volume 22, Issue 12, pp. 2247 - 2256
...) and its effect on bone remodeling and angiogenesis in relapsed/refractory myeloma. Bortezomib (1.0 mg/m(2)) was given on days 1, 4, 8, 11, oral melphalan... 
Neovascularization, Physiologic - drug effects | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Bone Remodeling - drug effects | Bone and Bones - drug effects | Antineoplastic Agents, Hormonal - adverse effects | Multiple Myeloma - drug therapy | Melphalan - adverse effects | Bone and Bones - metabolism | Aged, 80 and over | Adult | Female | Boronic Acids - administration & dosage | Immunosuppressive Agents - administration & dosage | Multiple Myeloma - physiopathology | Biomarkers - metabolism | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Cytokines - metabolism | Antineoplastic Agents, Hormonal - administration & dosage | Survival Rate | Thalidomide - administration & dosage | Multiple Myeloma - metabolism | Melphalan - administration & dosage | Pyrazines - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Antineoplastic Agents, Alkylating - adverse effects | Antimitotic agents | Multiple myeloma | Physiological aspects | Genetic aspects | Dosage and administration | Drug therapy, Combination | Neovascularization | Research | Drug therapy | Antineoplastic agents | Health aspects | Index Medicus
Journal Article
Blood, ISSN 1528-0020, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
Life Sciences & Biomedicine | Hematology | Science & Technology | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 09/2017, Volume 178, Issue 5, pp. 772 - 780
Summary We compared the efficacy and safety of gemcitabine, cisplatin, prednisone and thalidomide (GDPT) with standard CHOP regimen (cyclophosphamide,... 
GDPT | peripheral T‐cell lymphoma | chemotherapy | safety | efficacy | peripheral T-cell lymphoma | Life Sciences & Biomedicine | Hematology | Science & Technology | Prednisolone - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, T-Cell, Peripheral - metabolism | Biomarkers, Tumor - metabolism | Vincristine - administration & dosage | Adult | Deoxycytidine - adverse effects | Female | Gene Expression Regulation, Neoplastic - drug effects | Doxorubicin - administration & dosage | Thalidomide - adverse effects | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Deoxycytidine - administration & dosage | RNA, Messenger - genetics | Lymphoma, T-Cell, Peripheral - genetics | Treatment Outcome | Thalidomide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Cisplatin - adverse effects | RNA, Neoplasm - genetics | Vincristine - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Doxorubicin - adverse effects | Antimitotic agents | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Prednisone | Non-Hodgkin's lymphomas | Antineoplastic agents | T cells | Biological markers | Steroids | Cancer | Therapy | Gemcitabine | Toxicity | Lymphocytes T | Gene expression | Survival | Patients | Doxorubicin | Vincristine | Lymphoma | Cisplatin | Cyclophosphamide | Biomarkers | ERCC1 protein | Remission | Lymphomas | Safety | Thalidomide | T-cell lymphoma | Acute toxicity | Index Medicus
Journal Article